Secretory carcinoma of the breast: A case report

被引:6
作者
Pohlodek, Kamil [1 ]
Meciarova, Iveta [2 ]
Grossmann, Petr [3 ,4 ]
Martinek, Petr [4 ]
Kinkor, Zdenek [3 ,4 ]
机构
[1] Comenius Univ, Fac Med, Dept Gynecol & Obstet 2, Bratislava, Slovakia
[2] Alpha Med Pathol Ltd, Bratislava, Slovakia
[3] Charles Univ Prague, Fac Med Plzen, Dept Pathol, Prague, Czech Republic
[4] Biopt Lab Ltd, Plzen, Czech Republic
关键词
Breast cancer; Breast imaging; Breast surgery; Sectretory carcinoma; Immunohistochemistry; Fluorescence in situ hybridization; Case report; FUSION;
D O I
10.1016/j.ijscr.2019.02.029
中图分类号
R61 [外科手术学];
学科分类号
摘要
INTRODUCTION: Secretory breast carcinoma (SBC) is a rare breast tumor which accounts for < 0.15% of all breast cancers. It was originally described as a juvenile breast carcinoma, occurring in young children and adolescent women. SBC is associated with a characteristic balanced translocation, t(12;15), that creates aETV6-NTRK3 gene fusion. PRESENTATION OF CASE: A 52-year-old Caucasian woman had palpable lump in her right breast. After breast imaging examination (BI-RADS 4b) and preoperative core-needle biopsy with suspicion of SBC a breast conserving therapy was performed. The diagnosis of SBC was confirmed through immunohistochemistry and cytogenetic examination of the tumor. The patient is now 22 months post-surgery and remains disease-free. DISCUSSION: Recent studies reported that the disease occurs at a later age than previously recognized, and is associated with good long-term survival. In breast imaging it may mimic a benign tumor. Immunohistochemistry and cytogenetic analysis of the tumor are crucial for confirmation of SBC. CONCLUSION: There is no consensus with regard to the best treatment strategy for patients with SBC. Breast conserving therapy with sentinel lymph nodes biopsy is at present the first choice treatment. Further research for a specific NTRK3 tyrosine kinase inhibitor could lead to the discovery of a new targeted treatment of this tumor. (C) 2019 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.
引用
收藏
页码:74 / 77
页数:4
相关论文
共 17 条
[1]   The SCARE Statement: Consensus-based surgical case report guidelines [J].
Agha, Riaz A. ;
Fowler, Alexander J. ;
Saeta, Alexandra ;
Barai, Ishani ;
Rajmohan, Shivanchan ;
Orgill, Dennis P. ;
Afifi, Raafat ;
Al-Ahmadi, Raha ;
Albrecht, Joerg ;
Alsawadi, Abdulrahman ;
Aronson, Jeffrey ;
Ather, M. Hammad ;
Bashashati, Mohammad ;
Basu, Somprakas ;
Bradley, Patrick ;
Chalkoo, Mushtaq ;
Challacombe, Ben ;
Cross, Trent ;
Derbyshire, Laura ;
Farooq, Naheed ;
Hoffman, Jerome ;
Kadioglu, Huseyin ;
Kasivisvanathan, Veeru ;
Kirshtein, Boris ;
Klappenbach, Roberto ;
Laskin, Daniel ;
Miguel, Diana ;
Milburn, James ;
Mousavi, Seyed Reza ;
Muensterer, Oliver ;
Ngu, James ;
Nixon, Iain ;
Noureldin, Ashraf ;
Perakath, Benjamin ;
Raison, Nicholas ;
Raveendran, Kandiah ;
Sullivan, Timothy ;
Thoma, Achilleas ;
Thorat, Mangesh ;
Valmasoni, Michele ;
Massarut, Samuele ;
D'cruz, Anil ;
Vasudevan, Baskaran ;
Giordano, Salvatore ;
Roy, Gaurav ;
Healy, Donagh ;
Machado-Aranda, David ;
Carroll, Bryan ;
Rosin, David .
INTERNATIONAL JOURNAL OF SURGERY, 2016, 34 :180-186
[2]   Secretory carcinoma of the breast [J].
Amott, DH ;
Masters, R ;
Moore, S .
BREAST JOURNAL, 2006, 12 (02) :183-183
[3]   NTRK fusion-positive cancers and TRK inhibitor therapy [J].
Cocco, Emiliano ;
Scaltriti, Maurizio ;
Drilon, Alexander .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (12) :731-747
[4]   Secretory Breast Carcinoma A Histopathologic and Genomic Spectrum Characterized by a Joint Specific ETV6-NTRK3 Gene Fusion [J].
Del Castillo, Marie ;
Chibon, Frederic ;
Arnould, Laurent ;
Croce, Sabrina ;
Ribeiro, Agnes ;
Perot, Gaelle ;
Hostein, Isabelle ;
Geha, Sameh ;
Bozon, Catherine ;
Garnier, Agnes ;
Lae, Marick ;
Vincent-Salomon, Anne ;
MacGrogan, Gaetan .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (11) :1458-1467
[5]   Metastatic secretory breast cancer. Non-responsiveness to chemotherapy: Case report and review of the literature [J].
Herz, H ;
Cooke, B ;
Goldstein, D .
ANNALS OF ONCOLOGY, 2000, 11 (10) :1343-1347
[6]   Secretory carcinoma of the breast: Results from the survival, epidemiology and end results database [J].
Horowitz, David P. ;
Sharma, Charu S. ;
Connolly, Eileen ;
Gidea-Addeo, Daniela ;
Deutsch, Israel .
BREAST, 2012, 21 (03) :350-353
[7]   Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum [J].
Lae, Marick ;
Freneaux, Paul ;
Sastre-Garau, Xavier ;
Chouchane, Olfa ;
Sigal-Zafrani, Brigitte ;
Vincent-Salomon, Anne .
MODERN PATHOLOGY, 2009, 22 (02) :291-298
[8]   Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study [J].
Laetsch, Theodore W. ;
DuBois, Steven G. ;
Mascarenhas, Leo ;
Turpin, Brian ;
Federman, Noah ;
Albert, Catherine M. ;
Nagasubramanian, Ramamoorthy ;
Davis, Jessica L. ;
Rudzinski, Erin ;
Feraco, Angela M. ;
Tuch, Brian B. ;
Ebata, Kevin T. ;
Reynolds, Mark ;
Smith, Steven ;
Cruickshank, Scott ;
Cox, Michael C. ;
Pappo, Alberto S. ;
Hawkins, Douglas S. .
LANCET ONCOLOGY, 2018, 19 (05) :705-714
[9]  
Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth
[10]   Secretory breast carcinoma: A report of three cases and a review of the literature [J].
Lee, Seung Geun ;
Jung, Seung Pil ;
Lee, Hye Yoon ;
Kim, Sinill ;
Kim, Hoon Yub ;
Kim, Insun ;
Bae, Jeoung Won .
ONCOLOGY LETTERS, 2014, 8 (02) :683-686